APIs and Excipients

Facilitating API Delivery with Nanoscale Solutions

July 02, 2019

Nanotechnology is enabling enhanced bioavailability, improved stability, and targeted delivery of challenging APIs.

FDA Approves Amgen and Allergan's Biosimilar to Herceptin

June 24, 2019

The biosimilar, Kanjinti, is approved for all indications of Herceptin, which includes treating breast, gastric, and gastroesophogeal cancers.

Concept Life Sciences Opens New API Facility in UK

June 19, 2019

New CDMO facility supports early-stage API manufacturing and scale up.

Lonza Expands HPAPI Capacity

June 17, 2019

Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.

Pfizer to Acquire Array BioPharma

June 17, 2019

Pfizer’s acquisition of Array BioPharma expands the company’s pipeline of investigational cancer therapies.

Enabling Technologies Advance Poorly Soluble Highly Potent APIs

June 02, 2019

Excipients and new processing techniques can make a real difference in the development of highly potent therapies.

FDA OKs Gene Therapy for Pediatric Spinal Muscular Atrophy

May 24, 2019

The agency has approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy to treat pediatric spinal muscular atrophy.

ProBioGen, Abcuro Partner on New Gen Biotherapeutics

May 23, 2019

The companies will develop a new generation of biotherapeutics from cell-line development through to GMP manufacturing.

Starch-Based Excipient for Direct Compression

May 16, 2019

StarTab from Colorcon was designed to ensure functionality and stability for direct compression tableting.

A Study of Leachable Silicone Oil in Simulated Biopharmaceutical Formulations

May 15, 2019

Leachable silicone oil may have an effect on large-molecule APIs, making it important to establish a robust analytical method to detect and quantify the substance.